Applied Biosystems and Myriad Proteomics Announce Research Collaboration to Develop Technologies and Applications for Proteomics.Business Editors/Medical Writers BIOWIRE2K FOSTER CITY, Calif. & SALT LAKE CITY--(BW HealthWire)--Aug. 13, 2002 Applied Biosystems Applied Biosystems, Inc. (formerly NASDAQ: ABIO) is the original name of a pioneer biotechnology company founded in 1981 in Foster City, California, among the Silicon Valley cities of the southern San Francisco Bay Area. (NYSE NYSE See: New York Stock Exchange :ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, and Myriad Proteomics Inc., a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. founded by Hitachi, Ltd., Friedli Corporate Finance, Oracle Corporation and Myriad Genetics Myriad Genetics is a leading biopharmaceutical company focused on understanding the relationship between genes, proteins and human diseases in order to develop the next generation of therapeutic and molecular diagnostic products. , Inc., today announced a collaboration to develop new technologies and applications for proteomics. Myriad Proteomics intends to use the Applied Biosystems 4700 Proteomics Analyzer with TOF/TOF(TM) Optics as a major platform in its efforts to map the human proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. and to identify drug targets for the prevention and treatment of human disease. Financial terms of the agreement were not disclosed. The collaboration will focus on the development of more effective ways to analyze proteins and pathways that comprise complex biological systems, using mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. , protein chemistry and bioinformatics. The effort will combine Applied Biosystems' expertise in mass spectrometry and advanced proteomics technologies with Myriad Proteomics' extensive expertise and technology in protein-protein interactions and protein complex analysis. "We believe that this collaboration may lead to new and more productive workflows using the Applied Biosystems 4700 Proteomics Analyzer in discovery proteomics including potentially enhanced approaches in protein-protein interaction studies," said Stephen A. Martin, Ph.D., Director of the Proteomics Research Center at Applied Biosystems. "In addition, we expect to gain insight into advanced applications utilizing the 4700 analyzer for proteomics." "We are excited about the combination of capabilities afforded by the Applied Biosystems 4700 Proteomics Analyzer. It will enable us to develop workflows which more efficiently analyze the multiprotein complexes we isolate, which effectively allows us to identify novel protein interactions on a systems scale," said Sudhir Sahasrabudhe, Ph.D., Chief Scientific Officer of Myriad Proteomics. "Additionally, the collaboration with Applied Biosystems should accelerate the implementation of processes leading to Myriad Proteomics' identification of novel drug targets." Scientists from both Applied Biosystems' Proteomics Research Center (PRC) in Framingham, MA and Myriad Proteomics' new laboratory and office site in Salt Lake City are expected to collaborate on the project. The PRC is leveraging Applied Biosystems existing proteomics expertise and internal research capabilities while facilitating collaboration with complementary research and technology partners. The goal is to achieve advances in the production of high quality information by means of significant improvements in throughput, automation, sensitivity and cost efficiency. The Applied Biosystems 4700 Proteomics Analyzer, introduced in January 2002, is the first commercial instrument to employ the new, high-speed Matrix Assisted Laser Desorption Desorption A process in which atomic and molecular species residing on the surface of a solid leave the surface and enter the surrounding gas or vacuum. Ionization ionization: see ion. ionization Process by which electrically neutral atoms or molecules are converted to electrically charged atoms or molecules (ions) by the removal or addition of negatively charged electrons. (MALDI MALDI Matrix-Assisted Laser Desorption/Ionization ) source and Applied Biosystems TOF/TOF(TM) Optics, creating advanced Tandem Time of Flight mass spectrometry technology. This technology combination permits fast, accurate identification and characterization of protein samples at throughput rates of as much as 1000 samples per hour - up to ten times faster than current technology. This system could be useful in making the drug development process more efficient and cost effective. About Applera Corporation and Applied Biosystems Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. The Celera Genomics Group (NYSE:CRA See Community Reinvestment Act. ), located in Rockville, MD and South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its genomic and proteomics technology platforms to identify drug targets and diagnostic marker candidates and to discover novel therapeutics. Its Celera Discovery System(TM) online platform, marketed exclusively through the Applied Biosystems Knowledge Business, is an integrated source of information based on the human genome and other biological and medical sources. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostics tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available on the World Wide Web at www.appliedbiosystems.com. About Myriad Proteomics, Inc. Myriad Proteomics, Inc., a private company, is a leader in employing mass spectrometry and yeast two hybrid technologies in a high throughput production environment to discover and analyze protein-protein interactions. Myriad Proteomics intends to utilize its proprietary technologies and processes to define a comprehensive human protein interaction map and, in combination with high throughput screening and validation techniques, to enhance protein based drug discovery working with partners in the pharmaceutical industry. The Company maintains its principal offices and laboratories at 2150 West Dauntless Ave., Salt Lake City, UT 84116. The telephone number is 801.303.1700. Certain statements in this press release are forward-looking. These may be identified by "believe," "expect," and "should" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on development of new products; (2) and other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. Note to Editors: Applied Biosystems is a registered trademark and Applera, Celera, Celera Diagnostics, and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the US and certain other countries. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion